Statins Tied to Lower Community-Acquired Staph Infection Risk

Share this content:
Statins Tied to Lower Community-Acquired Staph Infection Risk
Statins Tied to Lower Community-Acquired Staph Infection Risk

WEDNESDAY, Oct. 11, 2017 (HealthDay News) -- Statin use is associated with a decreased risk of community-acquired Staphylococcus aureus bacteremia (CA-SAB), particularly in long-term users, according to a study published in the October issue of Mayo Clinic Proceedings.

Jesper Smit, M.D., Ph.D., from Aalborg University Hospital in Denmark, and colleagues used population-based medical registries to identify 2,638 adults with first-time CA-SAB and 26,379 population controls matched for age, sex, and residence in northern Denmark (Jan. 1, 2000, through Dec. 31, 2011). Statin users were characterized as current users (new or long-term use), former users, and nonusers.

The researchers found that compared with nonusers, current statin users experienced markedly decreased risk of CA-SAB (adjusted odds ratio [OR], 0.73; 95 percent confidence interval, 0.63 to 0.84). The adjusted OR was 0.96 (95 percent confidence interval, 0.6 to 1.51) for new users, 0.71 (95 percent confidence interval, 0.62 to 0.82) for long-term users, and 1.12 (95 percent confidence interval, 0.94 to 1.32) for former users, all versus nonusers. Increasing intensity of statin use was associated with decreased CA-SAB risk compared with nonusers (adjusted OR, 0.84 [95 percent confidence interval, 0.68 to 1.04] for current users with daily dosages <20 mg/day; 0.71 [95 percent confidence interval, 0.58 to 0.87] for 20 to 39 mg/day, and 0.63 [95 percent confidence interval, 0.49 to 0.81] for 40 mg/day or more). However, there were no differences in CA-SAB risk with increases in duration of statin use.

"Our results warrant confirmation in other settings and study designs, and the biological mechanisms by which statin treatment may protect against CA-SAB should be explored further," conclude the authors.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »